Introduction {#sec1_1}
============

Burning mouth syndrome (BMS) is a chronic pain disorder characterized by burning and stinging of the oral cavity in the absence of any organic disease. BMS typically affects middle-aged women \[[@B1]\]. A highly characteristic feature of this disease is the presence of a completely normal-appearing oral mucosa in association with the complaint of an intensely burning mouth or tongue. The tissue has the same color as that of the surrounding tissue, with normal distribution of tongue papillae. So far, there is no satisfactory treatment for BMS. Hormonal changes, neurologic problems, and idiopathic disease are as difficult to identify as they are to treat.

The number of hepatitis C virus (HCV) carriers in Japan is estimated to be 1.5--2 million. HCV infection is the leading cause of liver cirrhosis and cancer, and also induces extrahepatic manifestations such as lichen planus \[[@B2], [@B3]\]. We previously reported the visual analog scale (VAS) and effects of REFRECARE-H® (EN Otsuka Pharmaceutical Co., Ltd.), a hinokitiol-containing oral care gel, on patients with oral lichen planus associated with HCV infection \[[@B4]\]. REFRECARE-H® is a therapeutic dentifrice containing hinokitiol, which can remove dental stains and general oral debris, and is effective in the prevention of breath odor and gum diseases.

HCV also presents with a psychiatric challenge. Patients with HCV are more likely to have psychiatric disorders, with depression being the most frequent and clinically important \[[@B5]\]. Herein, we report the case of a 42-year-old woman with HCV infection, who was diagnosed with BMS and, subsequently, treated with REFRECARE-H®. VAS is a simple and frequently used method for evaluating variations in pain intensity \[[@B6]\]. Therefore, we investigated the VAS and effects of REFRECARE-H® on this patient.

Case Presentation {#sec1_2}
=================

In July 2008, a 42-year-old Japanese female visited the Kurume University Hospital (Fukuoka, Japan) complaining of glossal discomfort before interferon treatment for chronic hepatitis C. She was diagnosed with BMS by a specialist oral surgeon. No signs or symptoms of oral lichen planus, Sjögren\'s syndrome, *Candida albicans*, and oral cancer were observed in the patient\'s oral cavity. There was no history of blood transfusion, tattoo, or injection drug use. Moreover, the patient was not a habitual alcohol drinker or smoker. Subsequently, she received Peg-interferon alpha-2b and ribavirin therapy for chronic hepatitis C for 48 weeks, but did not reach sustained virologic response. At the age of 44 (in 2010), the patient received direct-acting antivirals, daclatasvir (NS5A inhibitor) plus Peg-interferon alpha-2a and ribavirin for 24 weeks. Eventually, the eradication of HCV was successful in the patient. However, after achieving a sustained virologic response following the treatment, the discomfort in the oral mucosa did not disappear completely.

At the age of 51 (in 2016), she consulted with the same oral surgeon about the intraoral discomfort, but no organic abnormality was found in the mouth. In February 2017 (age 51), she visited the oral surgeon again with a complaint of burning sensation and tingling pain in the tongue. She did not experience any taste disorder. Alternatively, she was under medication (etizolam and Chinese medicine) for symptoms related to menopause; however, the intraoral symptoms were not relieved.

REFRECARE-H®, an oral care gel, was applied as a thin layer on the oral membrane after each meal for 60 days. A VAS is a horizontal line, 100 mm in length, anchored by word descriptors at each end, as illustrated in Figure [1](#F1){ref-type="fig"}. The patients marked on the line the point that they felt represented their perception of their current state, such as tingling pain of the tongue during rest, oral discomfort, breath odor, dry mouth, oral pain at mealtimes, sleep disorder, depressive mood, and jitteriness. The VAS score was determined by measuring, in millimeters, from the left hand end of the line to the point marked by the patient.

The patient checked the VAS every day form February 2, 2017 to April 30, 2017, before application of REFRECARE-H®, 2 months during application of the gel, and 1 month after the end of application (REFRECARE-H® free). Mean values and changes of VAS are shown in Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, respectively. Application of REFRECARE-H® improved the quality of life such as tingling pain, oral discomfort, breath odor, sleep disorder, depressive mood, and jitteriness; the improvement in symptoms continued for 30 days after application of REFRECARE-H®. Hence, we believe that REFRECARE-H® could be effective in reducing the symptoms associated with BMS.

Discussion {#sec1_3}
==========

The prevalence of BMS is thought to range from 0.7 to 15% \[[@B7], [@B8], [@B9]\]. It affects middle-aged and older women (mean age, 50--60 years), with a female-to-male ratio varying from 3:1 to 16:1 \[[@B10], [@B11]\].

The etiology of BMS is varied, making it difficult to decipher the disease clinically \[[@B1]\]. The symptoms of pain appear to be due to various reasons such as microorganisms (especially *Candida albicans*), xerostomia with Sjögren\'s syndrome, nutritional deficiencies, anemia, hormone imbalance, neuropsychiatric abnormalities, diabetes mellitus, mechanical trauma, and idiopathic causes.

The present case was complicated as the patient presented with hepatitis C at the onset of BMS. Patients with hepatitis C have high rates of psychological symptoms and reduced quality of life when compared with the general population \[[@B12], [@B13]\]. The prevalence of depression with HCV infection is reported to be 24--28% \[[@B5]\]. In this report, the reason for the onset of BMS is unknown, but HCV infection may have acted as a trigger for the development of BMS.

Antidepressant therapy plays a major role in the management of BMS once other precipitating factors have been excluded \[[@B1]\]. Tricyclic antidepressants or a selective serotonin reuptake inhibitor may be used \[[@B14], [@B15]\]. In addition, recent reports have suggested the role of daily low-dose benzodiazepines such as clonazepam \[[@B16]\].

Subclinical *Candida* infection has been suggested as one of the etiological factors in patients with BMS \[[@B17]\]. REFRECARE-H**®**, a gel with efficacy against *Candida albicans*, might aid in minimizing the tingling pain and oral discomfort, thereby improving the quality of life of the patient in this case report.

We have previously demonstrated that REFRECARE-H**®** was instrumental in decreasing the subjective symptoms in patients with oral lichen planus \[[@B4]\]. In the present study, application of REFRECARE-H® improved the quality of life of the patient in terms of dry mouth, breath odor, oral freshness, oral pain during rest, oral pain at mealtimes, taste disorder, loss of appetite, sleep disorder, depressive mood, and jitteriness.

In conclusion, this report demonstrates that oral care gel can be used to address the subjective symptoms and improve the quality of life of a patient with BMS.
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![Visual analog scale (VAS) of 8 items. A VAS is a horizontal line, 100 mm in length, anchored by word descriptors at each end.](crg-0011-0480-g01){#F1}

![The distributions of visual analog scale score before, during, and after the application of REFRECARE-H®. All subjective symptoms decreased during and after the application.](crg-0011-0480-g02){#F2}

###### 

Visual analog scale scores before, during, and after the application of REFRECARE-H^®^

  Subjective symptoms                       Before application (Feb. 2, 2017), mm   During application (from Feb. 3 to Mar. 31, 2017) (mean ± SD), mm   After application (from Apr. 1 to Apr. 30, 2017) (mean ± SD), mm
  ----------------------------------------- --------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------
  Tingling pain in the tongue during rest   87                                      20.98±26.46                                                         10.20±18.77
  Oral discomfort                           15                                      11.75±5.49                                                          3.53±2.58
  Breath odor                               51                                      22.16±16.01                                                         2.87±2.64
  Dry mouth                                 0                                       0.26±1.36                                                           0
  Oral pain at mealtimes                    0                                       0                                                                   0
  Sleep disorder                            72                                      63.18±18.00                                                         62.63±13.40
  Depressive mood                           73                                      53.47±16.31                                                         47.97±13.37
  Jitteriness                               52                                      41.23±20.45                                                         44.33±25.33
